Tyra Biosciences to Participate at September 2022 Investor Conferences

On September 8, 2022 Tyra Biosciences, Inc. ( Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, reported that management will participate at the following investor conferences (Press release, Tyra Biosciences, SEP 8, 2022, View Source [SID1234619292]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright’s 24th Annual Global Investment Conference

September 12-14th, 2022
A pre-recorded presentation will be available here on September 12th at 7am ET
Cantor Oncology, Hematology & HemeOnc Conference

September 28th, 2022, in NY
Panel discussion titled, "Resistant to Resistance: Approaches to Address Resistance in Oncology", on September 28th at 11:30am ET